Skip to main content

Ronawk

MaterialsOlathe, KS, USAFounded 2019· One of 961 Materials companies tracked by AMPulse

Develops 3D bioprinted hydrogel substrates (Bio-Blocks) for tissue-mimetic cell culture, eliminating subculture to accelerate research and therapeutic development.

CEO / Founder
A.J. Mellott
Team Size
11-50
Stage
Active
Total Funding
$8M
Latest Round
Series A
Key Investors
Manhattan Venture Partners; MassChallenge; Digital Sandbox KC

Technology & Products

Key Products

Bio-Blocks (T-Blocks, X-Blocks, E-Blocks); Bio-OS platform; 3D printing services; Imaging services

Technological Advantage

Patented 3D porous hydrogel design (verified in publications) enables 95% cell retrieval vs. 70% industry standard; defensible via trade secrets and pending patents.

Differentiation

Value Proposition

Reduces cell culture time by eliminating subculture, increasing biological yield by 30-50%, lowering contamination risk by 60%, and cutting labor costs by 40% for scalable therapeutic production.

How They Differentiate

3x higher cell yield retention (95% vs. 70% for Organovo) and eliminates subculture vs. competitors requiring frequent passaging; 40% lower cost-per-cell for large-scale production.

Market & Competition

Target Customers

Biotech firms, CDMOs, CROs, biopharma companies, academic labs, regenerative medicine partners

Industry Verticals

Biotechnology; Regenerative Medicine; Pharmaceuticals; Life Sciences

Competitors

Organovo; CELLINK; Allevi

Growth & Milestones

Growth Metrics

Revenue grew 200% YoY; expanded team from 15 to 20 employees in 2023; secured partnerships with 10+ biotech firms.

Major Milestones

Founded in 2019; Launched Bio-Block Universe in 2021; Closed $1.5M seed round in 2023; Secured $6M Series A in May 2023; Partnered with B9Creations in June 2024

Notable Customers

A handful of academic clients are using Ronawk's technology, including national universities and academic institutions.

https://ronawk.com

Why this company matters

Ronawk develops 3D bioprinted hydrogel substrates called Bio-Blocks that mimic in vivo microenvironments for cell culture. The technology eliminates the need for subculture, a standard but labor-intensive step in conventional 2D and scaffold-based systems. This reduces contamination risk by 60% and lowers labor costs by 40%, according to the company.

The core product line includes T-Blocks, X-Blocks, and E-Blocks, supported by the Bio-OS platform for workflow management. Ronawk's patented porous hydrogel design enables 95% cell retrieval, compared to an industry average of 70%. The company uses material extrusion (MEX) bioprinting to fabricate these substrates, targeting biotech firms, CDMOs, CROs, and academic labs in regenerative medicine and pharmaceutical development.

Ronawk has raised $8 million in total funding from investors including Manhattan Venture Partners and MassChallenge. Revenue grew 200% year-over-year, and the team expanded from 15 to 20 employees in 2023. Key partnerships include B9Creations for additive manufacturing and Cellipont Bioservices for scalable mesenchymal stem cell expansion. The company competes with Organovo, CELLINK, and Allevi, differentiating through higher cell yield and the elimination of passaging.

A key open question is whether Ronawk's hydrogel substrates can achieve the throughput and reproducibility required for large-scale therapeutic manufacturing, a hurdle that has limited adoption of 3D cell culture in regulated biopharma production.